# Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

> **NCT02914613** · PHASE1,PHASE2 · COMPLETED · sponsor: **OcuTerra Therapeutics, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** SF0166 Topical Ophthalmic Solution

## Key facts

- **NCT ID:** NCT02914613
- **Lead sponsor:** OcuTerra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-24
- **Primary completion:** 2017-05-16
- **Final completion:** 2017-05-16
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914613, "Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02914613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*